Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusAGEN -2.32%43 9-Day RSI is 56.94 as of Aug. 18, 2026. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 1,417 Biotechnology companies, Agenus ranks worse than 70.57% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-08-18), Agenus's 9-Day RSI is 56.94.
The industry rank for Agenus's 9-Day RSI or its related term are showing as below:
AGEN's 9-Day RSI is ranked worse than 70.57% of 1417
companies
in the Biotechnology industry
Industry Median: 53.45
vs AGEN: 56.94
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Agenus 9-Day RSI Related Terms
AGEN vs FULC, IRD, TTRX: 9-Day RSI Comparison
For the Biotechnology subindustry, Agenus's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Agenus's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus (AGEN) has a 9-Day RSI of 56.94 as of Aug. 18, 2026. According to the industry distribution chart, Agenus ranks #1000 out of 1417 companies in the Biotechnology industry, placing it in the top 70.6%.
Is Agenus' 9-Day RSI too high?
Agenus' current 9-Day RSI is 56.94. The Biotechnology industry median 9-Day RSI is 53.45. Agenus' value of 56.94 is 6.5% above this industry median. Based on the distribution chart, Agenus ranks #1000 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' 9-Day RSI compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #1000 out of 1417 companies for 9-Day RSI. This places Agenus in the lower half of its industry. The industry median 9-Day RSI is 53.45. Agenus' value of 56.94 is 6.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.45, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agenus's current 9-Day RSI of 56.94 is 6.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current 9-Day RSI is 56.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.16 — trading 89.3% above its estimated fair value. The current 9-Day RSI is 56.94 and 6.5% above the Biotechnology industry median of 53.45. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Agenus (AGEN), the current 9-Day RSI is 56.94 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (AGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for AGEN:
9-Day RSI: 56.94
GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
Industry Position: 6.5% above the Biotechnology median (#1000 of 1417)
No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score
Get the complete analysis for AGEN
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGEN has been successfully added to your 
